search - Mayo Clinic Laboratories

Web:	mayocliniclabs.com
Email:	mcl@mayo.edu
Telephone:	800-533-1710
International:	+1 855-379-3115
Values are valid only on day of printing

Web:

mayocliniclabs.com

Email:

mcl@mayo.edu

Telephone:

800-533-1710

International:

+1 855-379-3115

Values are valid only on day of printing

Search Results

Site Search

New tests launched in March - Insights

In March 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Nonradioactive assay helps diagnose heparin reaction - Insights

Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the...

Novel biomarkers added to movement disorders profile - Insights

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.

Improving diagnosis and treatment of Helicobacter pylori - Insights

Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.

Melanoma panel provides more tumor information - Insights

In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

Comprehensive panel boosts GIST diagnosis sensitivity - Insights

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) - Insights

Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide...